Condensed Consolidated Statements of Changes in Shareholders’ Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Non-controlling Interest	Accumulated Other Comprehensive Income (Loss)
Beginning balance (in shares) at Dec. 31, 2023		299,215,160
Beginning balance at Dec. 31, 2023	$ 283,825	$ 30	$ 2,136,870	$ (1,845,542)	$ (11,751)	$ 4,218
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		2,042
Exercise of stock options	2		2
Delivery of common stock underlying restricted stock units (in shares)		507,198
Stock-based compensation	11,873		11,873
Foreign currency translation adjustment	(3,015)					(3,015)
Net loss attributable to non-controlling interest	574				574
Net income attributable to common shareholders	(56,010)			(56,010)
Ending balance (in shares) at Mar. 31, 2024		299,724,400
Ending balance at Mar. 31, 2024	$ 236,101	$ 30	2,148,745	(1,901,552)	(12,325)	1,203
Beginning balance (in shares) at Dec. 31, 2024	339,144,854	339,144,854
Beginning balance at Dec. 31, 2024	$ 180,782	$ 34	2,219,002	(2,017,796)	(15,588)	(4,870)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)	2,150,631	2,150,631
Exercise of stock options	$ 2,700		2,700
Delivery of common stock underlying restricted stock units (in shares)		244,312
Stock-based compensation	11,868		11,868
Foreign currency translation adjustment	5,197					5,197
Reduction in non-controlling interest	0		(4,237)		4,237
Net loss attributable to non-controlling interest	5				5
Net income attributable to common shareholders	$ 188,493			188,493
Ending balance (in shares) at Mar. 31, 2025	341,539,797	341,539,797
Ending balance at Mar. 31, 2025	$ 389,035	$ 34	$ 2,229,333	$ (1,829,303)	$ (11,356)	$ 327